Skip to content
Review

Dose equivalence calculation in radiotherapy: A Call for Standardization.

Sep 2026 · Medical Dosimetry · 1 citation · 35 references
Medicine

TL;DR

Urgent harmonization through validated models, standardized workflows with mandatory repopulation correction, voxel-based BED/EQD2 assessment, and clearly defined professional accountability is imperative to ensure consistent, safe patient care.

Abstract

Accurate dose equivalence calculations are essential in radiotherapy to balance tumor control with tissue preservation. Despite decades of research, clinical implementation remains highly variable. A structured workshop analysis involving radiation oncologists, medical physicists, and technicians revealed alarming heterogeneity: when applying equivalent dose models (LQ/LQL) to identical clinical scenarios, mean inter practitioner agreement reached only 25.8% (Jaccard index), with consensus as low as 10% for head-and-neck cases. Proposed dose-per-fraction adjustments for identical situations ranged from 1.8 to 2.5 Gy, representing 15 to 20% biological dose variations (Kruskal-Wallis on the distribution of proposed doses across participant responses, case 1: p=0.18 head and neck, p=0.032 breast, p=0.027 bladder; p<0.05 for the three remaining cases). This variability persists across treatment interruptions, hypofractionation, and reirradiation: nearly 50% of surveyed centers cannot compute biologically equivalent schedules using available tools. Root causes include systematic reliance on the linear-quadratic model beyond the fraction sizes for which it is best established, outdated radiobiological parameters, and omission of repopulation correction despite international guidelines. Clinical consequences are not theoretical: for a 7-day treatment gap, institutional practices vary from 1.8 to 2.5 Gy compensatory fractions, potentially resulting in 10 to 15 Gy equivalent dose differences. In reirradiation, heterogeneous dose summation compromises spinal cord protection where small errors translate to irreversible myelopathy risk. Current practice depends on local tradition rather than evidence, creating unacceptable geographic disparities. Urgent harmonization through validated models, standardized workflows with mandatory repopulation correction, voxel-based BED/EQD2 assessment, and clearly defined professional accountability is imperative to ensure consistent, safe patient care.

View source

Similar papers

Open access Oct 2026

Evaluation of online dose‐guided adaptive fractionation for intact prostate radiotherapy

Abstract Background Dose‐guided adaptive fractionation (DGAF) was proposed as a simpler alternative of adaptive radiation therapy, using organ variation simulation for proof of concept. However, its dosimetric benefit using actual daily anatomy changes in prostate cancer patients remains unclear. Purpose The purpose of...

G. Gevorkyan, Li-Bing Zhu, R. Tegtmeier et al. · 0 citations
Open access Oct 2026

Cohort-specific dosimetric and delivery tradeoffs for proton dynamic arc vs. IMPT for breast and chest wall irradiation.

Compared with conventional intensity-modulated proton therapy for breast/chest wall irradiation across diverse clinical anatomies, DynamicArc achieved target coverage comparable to IMPT and improved robustness pass rates for selected targets.

Kristen McConnell, R. Rohe, Valeriane Mcneill et al. · 0 citations
Review Open access Sep 2026

Dose Mapping and Accumulation for Re-Irradiation of Lung Cancers: Methodological Principles, Uncertainties, Quality Assurance, and Practical Clinical Considerations

Practical considerations in this article are intended to complement formal consensus guidance, institutional protocols, or patient-specific multidisciplinary judgment and support more defensible use of cumulative dose in lung re-irradiation.

M. Rosu-Bubulac, Hua-Liang Zhong, I. Chetty · 0 citations
Sep 2026

Dosimetric and radiobiological evaluation of a spatially fractionated core-boost strategy in lung metastases within 5 mm of the esophagus: Single-center plan-comparison study.

For lung metastases lying within 5 mm of the esophagus, organ-at-risk dose limits often force the prescription below the ablative range, lowering biologically effective dose and tumor control. We evaluated whether a simultaneous integrated boost to the tumor core, rather than dose reduction, is dosimetrically and radio...

I. H. Suyusal, O. Çolak, Ahmet Karagöz · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.